Japan Drug Makers Facing Patent Cliff Turn To Biotech Drugs
This article was originally published in PharmAsia News
Executive Summary
Several Japanese drug makers are betting on bioengineered drugs, with at least one awaiting regulatory approval, to counter the loss of patent protection for current blockbusters